Terina Martinez

Company: Critical Path Institute

Job title: Executive Director, Critical Path For Rare Neurodegenerative Diseases (Cp-Rnd)

Seminars:

8:40 Panel Discussion: Reflecting on Lessons Learned from PhII/III Failures to Drive Urgency for Novel CNS Biomarker Research 8:45 am

Evaluating past failures to identify key missteps, avoid repeating errors, and foster collective learning that propels the field forward with greater cohesion The blood-based biomarker revolution: Reviewing the latest progress to increase accessibility, sensitivity and scalability Evaluating the latest progress in neuroimaging technologies: Enhancing clinical value, navigating constraints, and integrating with fluid-based approaches Read more

day: Conference Day 1

9:30 Decoding Co-Pathologies to Refine Disease Definitions, Enhance Target Engagement, & Optimize Patient Stratification in Neurodegeneration 9:30 am

Navigating overlapping pathologies in AD, PD, ALS, and MS: tau, amyloid, αsynuclein, TDP-43, and others Quantifying and differentiating overlapping pathologies and their impact on diagnosis and treatment What deciphering co-pathologies means for patient stratification and therapeutic targetingRead more

day: Conference Day 2

2:00 Panel Discussion: Optimizing Imaging Endpoints, Mapping the Current Imaging Landscape & Emerging Tools in Neuroscience 2:00 pm

Review of Current Imaging Modalities: Overview of PET, MRI, fMRI, and other techniques used in neurodegenerative disease trials (e.g., AD, PD, MS, ALS) Limitations of Imaging Biomarkers in Clinical Trials: Challenges including accessibility, cost, patient burden, and limitations in sensitivity or specificity Innovations on the Horizon: Discussion of emerging imaging techniques and tools, including novel…Read more

day: Conference Day 2